Sort by
Keyphrases
Tumor Growth
100%
Treatment Outcome
100%
Patient Treatment
100%
Melanocytic Tumor
100%
Tumor Patients
100%
Pathogenic Germline Variant
100%
Variant Impact
100%
Kinase Insert Domain Receptor
100%
Genotype
30%
Tumor Response
15%
Response to Treatment
15%
Tumor Phenotype
15%
Lenvatinib
15%
Tumor Growth Kinetics
15%
Germ Cells
7%
Clinical Trials
7%
Murine Model
7%
High Incidence
7%
Targeted Therapy
7%
Angiogenesis
7%
Tumor Volume
7%
Tumor Size
7%
Murine Tumors
7%
Angiogenic
7%
Melanoma Cells
7%
Melanoma Patients
7%
Melanoma
7%
Anti-PD-1 Therapy
7%
Tumor-infiltrating Lymphocytes
7%
Antiangiogenic Therapy
7%
CD45
7%
Immune Checkpoint Inhibitor Therapy
7%
Immune-suppressive
7%
MAPK Inhibitors
7%
Melanoma B16
7%
Immune Checkpoint Inhibitor Treatment
7%
Dabrafenib
7%
Tumor Immunophenotype
7%
B16 Cell Line
7%
Synergistic Cytotoxicity
7%
Anti-VEGFR
7%
VEGFR Inhibition
7%
Medicine and Dentistry
Tumor Progression
100%
Vasculotropin Receptor 2
100%
Melanoma
100%
Germ Cell
100%
Treatment Outcome
100%
Neoplasm
38%
Immune Checkpoint Inhibitor
15%
Lenvatinib
15%
Clinical Trial
7%
Targeted Therapy
7%
Tumor
7%
Mitogen-Activated Protein Kinase
7%
Tumor Angiogenesis
7%
Cytotoxicity
7%
Melanoma Cell
7%
Tumor Infiltrating Lymphocyte
7%
Antiangiogenic Therapy
7%
Immunophenotyping
7%
Melanoma B16
7%
Dabrafenib
7%
B16 Cell Line
7%
Biochemistry, Genetics and Molecular Biology
Germline
100%
Germ Cell
100%
Tumor Progression
100%
Kinase Insert Domain Receptor
100%
Genotyping
30%
Tumor Volume
15%
Immune Checkpoint Inhibitor
15%
Mitogen-Activated Protein Kinase
7%
Wild Type
7%
Clinical Trial
7%
Angiogenesis
7%
Cytotoxicity
7%
Murine
7%
Tumor-Infiltrating Lymphocytes
7%
Immunophenotyping
7%
Dabrafenib
7%
Targeted Therapy
7%
Immunology and Microbiology
Kinase Insert Domain Receptor
100%
Germ Cell
100%
Tumor Volume
15%
Lenvatinib
15%
Immune Checkpoint Inhibitor
15%
Wild Type
7%
Angiogenesis
7%
Murine
7%
Cytotoxicity
7%
Melanoma Cell
7%
Tumor-Infiltrating Lymphocytes
7%
B16 Cell Line
7%